john r stanton @dcbigjohn
Or if you’re going to write on these drugs (which I agree is suspect and requires an immensely high bar) don’t name the drug or company and have a strict policy of never naming them, so polling driven policy decisions and stock price hyping become much less likely or profitable — PolitiTweet.org
Mike Lobikis @MLfromdeep
Important thread about reporting right now. I would add that I’ve seen “this has not gone through the peer review p… https://t.co/qzKXE26RBH
